Lunsotogene parvec

哌伦索托基

Report date: 2026/05/25 16:10:35

Base Information

Drug NameLunsotogene parvec
Drug Alias Namelunsotogene parvec-cwhaOtarmeniDB-OTO
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV1 vector
Mechanisms of ActionOtoferlin gene transference
TargetsOtoferlin
Therapy Area/IndicationsHearing Loss
Global Approved IndicationsHearing Loss
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/04/23
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDecibel Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc
Inactive CompaniesDecibel Therapeutics
Active IndicationsHearing Loss
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A